TY - JOUR
T1 - Time course characteristics of tolerance development to continuously infused antinociceptive agents in rat spinal cord
AU - Stevens, C. W.
AU - Yaksh, T. L.
N1 - Copyright:
Copyright 2004 Elsevier B.V., All rights reserved.
PY - 1989
Y1 - 1989
N2 - By using a constant-rate, fixed concentration intrathecal infusion model, the time course of change in hot plate (HP) response latencies over a 7-day period was examined in rats receiving constant infusion of saline (vehicle), morphine (MOR (2, 6 or 20 nmol/hr), sufentanil (SUF) (0.06, 0.2 or 0.6 nmol/hr), D-Ala2-MePhe4-Gly-ol5-enkephalin (DAMGO) (0.1, 0.3 or 1.0 nmol/hr) (mu opioids), D-Ala2-D-Leu5-enkephalin (DADLE) (2, 6 or 20 nmol/hr) (delta opioid), ST-91 (3, 10 or 30 nmol/hr) (alpha-2 agonist) or the combination of ST-91 + MOR. Three important observations were made: 1) A concentration-dependent elevation in HP latency was observed on day 1 (order of potency: DAMGO = SUF > MOR ≥ DADLE ≥ ST-91 + MOR ≥ ST-91) with a gradual return to saline-infused values observed for all concentrations of all drugs by 3 to 5 days. 2) The rate of tolerance development, estimated by calculation of the exponential decay half-life from peak day 1 HP, was not different as a function of drug dose. The area under the 7-day tolerance curve (response latency x day) was directly proportional to infusion concentration and to peak HP effect on day 1. These two calculations both suggest that the rate at which the tolerance adaptation of drug occurs to agonist effects is similar for agents acting upon mu, delta and alpha-2 receptors in rat spinal cord. 3) Plotting the concentration-effect curves observed for days 1 to 4 after infusion revealed that the degree of shift relative to day 1 (ED50 day x/ED50 day 1; x = 1-4) was rank ordered: MOR > ST-91 > DADL >> SUF = DAMGO = ST-91 + MOR. This observation supports the hypothesis that the degree of tolerance (as manifested by the magnitude of the shift over time during continuous infusion) may be dependent upon the receptor reserve or second messengers of that agent in that assay system.
AB - By using a constant-rate, fixed concentration intrathecal infusion model, the time course of change in hot plate (HP) response latencies over a 7-day period was examined in rats receiving constant infusion of saline (vehicle), morphine (MOR (2, 6 or 20 nmol/hr), sufentanil (SUF) (0.06, 0.2 or 0.6 nmol/hr), D-Ala2-MePhe4-Gly-ol5-enkephalin (DAMGO) (0.1, 0.3 or 1.0 nmol/hr) (mu opioids), D-Ala2-D-Leu5-enkephalin (DADLE) (2, 6 or 20 nmol/hr) (delta opioid), ST-91 (3, 10 or 30 nmol/hr) (alpha-2 agonist) or the combination of ST-91 + MOR. Three important observations were made: 1) A concentration-dependent elevation in HP latency was observed on day 1 (order of potency: DAMGO = SUF > MOR ≥ DADLE ≥ ST-91 + MOR ≥ ST-91) with a gradual return to saline-infused values observed for all concentrations of all drugs by 3 to 5 days. 2) The rate of tolerance development, estimated by calculation of the exponential decay half-life from peak day 1 HP, was not different as a function of drug dose. The area under the 7-day tolerance curve (response latency x day) was directly proportional to infusion concentration and to peak HP effect on day 1. These two calculations both suggest that the rate at which the tolerance adaptation of drug occurs to agonist effects is similar for agents acting upon mu, delta and alpha-2 receptors in rat spinal cord. 3) Plotting the concentration-effect curves observed for days 1 to 4 after infusion revealed that the degree of shift relative to day 1 (ED50 day x/ED50 day 1; x = 1-4) was rank ordered: MOR > ST-91 > DADL >> SUF = DAMGO = ST-91 + MOR. This observation supports the hypothesis that the degree of tolerance (as manifested by the magnitude of the shift over time during continuous infusion) may be dependent upon the receptor reserve or second messengers of that agent in that assay system.
UR - http://www.scopus.com/inward/record.url?scp=0013624569&partnerID=8YFLogxK
M3 - Article
C2 - 2795458
AN - SCOPUS:0013624569
SN - 0022-3565
VL - 251
SP - 216
EP - 223
JO - Journal of Pharmacology and Experimental Therapeutics
JF - Journal of Pharmacology and Experimental Therapeutics
IS - 1
ER -